Dynavax Technologies Corporation news

   Watch this stock
Showing stories 11 - 20 of about 89   

Articles published

DVAX 23.31 -0.38 (-1.60%)
price chart
Dynavax Technologies Corporation (DVAX) news: Dynavax: An Update On This ...
Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
Dynavax Receives Milestone Payments from AstraZeneca  Zacks.com
Related articles »  
Hedge Funds Are Crazy About Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corporation To the average investor, there are dozens of gauges shareholders can use to track publicly traded companies.
Dynavax: FDA Asks For Additional Safety Data  Seeking Alpha
Dynavax's hepatitis B vaccine delayed as FDA seeks more data  Reuters
Related articles »  
Dynavax: Assembling The A-Team
As I noted earlier this year, on Thursday, March 21, 2013, Dynavax Technologies Corporation (NASDAQ:DVAX) announced that David Novack joined the company as its Senior Vice President, Operations and Quality, effective March 25, 2013.
Related articles »  
DynaVax Technologies: The Small Cap Gem Focus Stock Of The Week (DVAX)
Their technology looks to inhibit Toll-like Receptors (TLRs). TLRs are key receptors of the innate immune system that can induce strong inflammatory responses.
Investors Watch List: Mylan N.V. (NASDAQ:MYL), Dynavax Technologies ...
Mylan N.V. (NASDAQ:MYL) belongs to Healthcare sector. Its net profit margin is 12.00% and weekly performance is 8.43%. On last trading day company shares ended up $72.40. Mylan N.V. (NASDAQ:MYL) distance from 50-day simple moving average ...
Interview with the CEO: Dynavax Technologies Corporation (DVAX)
Eddie Gray joined Dynavax Technologies Corporation as Chief Executive Officer and was appointed to the board in May 2013. Most recently, Mr. Gray served as the President of Pharmaceuticals Europe at GlaxoSmithKline plc (GSK) since 2008, and as ...
Dynavax Technologies (DVAX) Shares March Higher, Can It Continue? - Tale of ...
From this look, the company's future is quite favorable; as DVAX has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company. Want the latest recommendations ...
Dynavax: A Takeover Target?
With the announcement by the company that the FDA sent them a Complete Response Letter (NYSE:CRL), the stock once again was sent tumbling, this time below $2, before recovering to close just above that level Monday and Tuesday of this week.
Related articles »  
Momentum Builder Stocks Alert - Navios Maritime Partners L.P. (NYSE:NMM ...
On Monday, Following Stocks were among the �Top 100 Gainers� of U.S. Stock Market: Navios Maritime Partners L.P. (NYSE:NMM), Dynavax Technologies Corporation (NASDAQ:DVAX), TrueCar, Inc. (NASDAQ:TRUE), Walter Energy, Inc. (NYSE:WLT).
Dynavax Technologies Sets New 1-Year High at $23.19 (DVAX)
Dynavax Technologies Corporation (NASDAQ:DVAX) is a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases.